Norselegiline (BioDeep_00000002942)

   


代谢物信息卡片


n-[(2r)-1-Phenylpropan-2-yl]prop-2-yn-1-amine

化学式: C12H15N (173.1204)
中文名称:
谱图信息: 最多检出来源 not specific(not specific) 0%

分子结构信息

SMILES: C#CCNC(C)Cc1ccccc1
InChI: InChI=1S/C12H15N/c1-3-9-13-11(2)10-12-7-5-4-6-8-12/h1,4-8,11,13H,9-10H2,2H3/t11-/m1/s1

描述信息

D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors

同义名列表

4 个代谢物同义名

n-[(2r)-1-Phenylpropan-2-yl]prop-2-yn-1-amine; Norselegiline; N-Desmethylselegiline; Norselegiline



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 4 ACE2, CYP2B6, CYP2D6, CYP3A4
Peripheral membrane protein 2 ACHE, CYP2B6
Endoplasmic reticulum membrane 3 CYP2B6, CYP2D6, CYP3A4
Mitochondrion membrane 1 MAOA
Nucleus 1 ACHE
cytosol 2 GPT, MAOA
dendrite 1 MAOB
nucleoplasm 1 TMPRSS2
Cell membrane 4 ACE2, ACHE, CD5, TMPRSS2
Cytoplasmic side 2 MAOA, MAOB
Synapse 1 ACHE
cell surface 2 ACE2, ACHE
Golgi apparatus 1 ACHE
neuromuscular junction 1 ACHE
neuronal cell body 1 MAOB
plasma membrane 4 ACE2, ACHE, CD5, TMPRSS2
Membrane 7 ACE2, ACHE, CD5, CYP2D6, CYP3A4, MAOA, TMPRSS2
apical plasma membrane 1 ACE2
extracellular exosome 3 ACE2, GPT, TMPRSS2
endoplasmic reticulum 1 CYP2D6
extracellular space 2 ACE2, ACHE
perinuclear region of cytoplasm 1 ACHE
mitochondrion 3 CYP2D6, MAOA, MAOB
intracellular membrane-bounded organelle 3 CYP2B6, CYP2D6, CYP3A4
Microsome membrane 3 CYP2B6, CYP2D6, CYP3A4
Single-pass type I membrane protein 2 ACE2, CD5
Secreted 2 ACE2, ACHE
extracellular region 3 ACE2, ACHE, TMPRSS2
Mitochondrion outer membrane 2 MAOA, MAOB
Single-pass membrane protein 2 CYP2D6, MAOA
mitochondrial outer membrane 2 MAOA, MAOB
Extracellular side 1 ACHE
Cell projection, cilium 1 ACE2
external side of plasma membrane 1 CD5
Single-pass type II membrane protein 1 TMPRSS2
Apical cell membrane 1 ACE2
Membrane raft 1 ACE2
basement membrane 1 ACHE
cilium 1 ACE2
brush border membrane 1 ACE2
Lipid-anchor, GPI-anchor 1 ACHE
side of membrane 1 ACHE
endoplasmic reticulum lumen 1 ACE2
endocytic vesicle membrane 1 ACE2
mitochondrial envelope 1 MAOB
Single-pass type IV membrane protein 2 MAOA, MAOB
synaptic cleft 1 ACHE
[Transmembrane protease serine 2 catalytic chain]: Secreted 1 TMPRSS2
[Isoform H]: Cell membrane 1 ACHE
[Processed angiotensin-converting enzyme 2]: Secreted 1 ACE2
[Isoform 2]: Apical cell membrane 1 ACE2


文献列表

  • B Szende, G Barna, Kálmán Magyar. Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells. Journal of neural transmission (Vienna, Austria : 1996). 2010 Jun; 117(6):695-8. doi: 10.1007/s00702-010-0413-8. [PMID: 20454984]
  • Debra S Harris, Thomas Everhart, Peyton Jacob, Emil Lin, John E Mendelson, Reese T Jones. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. BMC clinical pharmacology. 2009 Aug; 9(?):13. doi: 10.1186/1472-6904-9-13. [PMID: 19646280]
  • K Magyar, I Szatmáry, G Szebeni, J Lengyel. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. Journal of neural transmission. Supplementum. 2007; ?(72):165-73. doi: 10.1007/978-3-211-73574-9_21. [PMID: 17982891]
  • Ayako Kuriki, Takeshi Kumazawa, Xiao-Pen Lee, Chika Hasegawa, Mitsuru Kawamura, Osamu Suzuki, Keizo Sato. Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Dec; 844(2):283-91. doi: 10.1016/j.jchromb.2006.07.019. [PMID: 16893687]
  • Robert Kronstrand, Johan Ahlner, Nil Dizdar, Göran Larson. Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. Journal of analytical toxicology. 2003 Apr; 27(3):135-41. doi: 10.1093/jat/27.3.135. [PMID: 12731653]
  • Matthew H Slawson, James L Taccogno, Rodger L Foltz, David E Moody. Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. Journal of analytical toxicology. 2002 Oct; 26(7):430-7. doi: 10.1093/jat/26.7.430. [PMID: 12422997]
  • M Katagi, M Tatsuno, H Tsutsumi, A Miki, T Kamata, H Nishioka, K Nakajima, M Nishikawa, H Tsuchihashi. Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man. Xenobiotica; the fate of foreign compounds in biological systems. 2002 Sep; 32(9):823-31. doi: 10.1080/00498250210144857. [PMID: 12396278]
  • Sanna Palovaara, Markku Anttila, Leena Nyman, Kari Laine. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. European journal of clinical pharmacology. 2002 Jul; 58(4):259-63. doi: 10.1007/s00228-002-0469-y. [PMID: 12136372]
  • K Laine, M Anttila, L Nyman, A Wahlberg, L Bertilsson. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. European journal of clinical pharmacology. 2001 May; 57(2):137-42. doi: 10.1007/s002280100289. [PMID: 11417445]
  • K T Kivistö, J S Wang, J T Backman, L Nyman, P Taavitsainen, M Anttila, P J Neuvonen. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. European journal of clinical pharmacology. 2001 Apr; 57(1):37-42. doi: 10.1007/s002280100278. [PMID: 11372588]
  • G W Carlile, R M Chalmers-Redman, N A Tatton, A Pong, K E Borden, W G Tatton. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Molecular pharmacology. 2000 Jan; 57(1):2-12. doi: . [PMID: 10617673]
  • B Szende, K Magyar, Z Szegedi. Apoptotic and antiapoptotic effect of (-)deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology (Budapest, Hungary). 2000; 8(3-4):249-55. doi: NULL. [PMID: 11225516]
  • K Laine, M Anttila, R Huupponen, O Mäki-Ikola, E Heinonen. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clinical neuropharmacology. 2000 Jan; 23(1):22-7. doi: 10.1097/00002826-200001000-00005. [PMID: 10682227]
  • M Hasegawa, K Matsubara, S Fukushima, C Maseda, T Uezono, K Kimura. Stereoselective analyses of selegiline metabolites: possible urinary markers for selegiline therapy. Forensic science international. 1999 Apr; 101(2):95-106. doi: 10.1016/s0379-0738(99)00015-8. [PMID: 10371041]
  • K Laine, M Anttila, A Helminen, H Karnani, R Huupponen. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. British journal of clinical pharmacology. 1999 Mar; 47(3):249-54. doi: 10.1046/j.1365-2125.1999.00891.x. [PMID: 10215747]
  • H Scheinin, M Anttila, M L Dahl, H Karnani, L Nyman, P Taavitsainen, O Pelkonen, L Bertilsson. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Clinical pharmacology and therapeutics. 1998 Oct; 64(4):402-11. doi: 10.1016/s0009-9236(98)90071-6. [PMID: 9797797]
  • S Rohatagi, J S Barrett, K E DeWitt, D Lessard, R J Morales. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. Biopharmaceutics & drug disposition. 1997 Nov; 18(8):665-80. doi: 10.1002/(sici)1099-081x(199711)18:8<665::aid-bdd47>3.0.co;2-a. [PMID: 9373724]
  • S Rohatagi, J S Barrett, K E DeWitt, R J Morales. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharmaceutics & drug disposition. 1997 Oct; 18(7):567-84. doi: 10.1002/(sici)1099-081x(199710)18:7<567::aid-bdd49>3.0.co;2-7. [PMID: 9330778]
  • E H Heinonen, M I Anttila, H L Karnani, L M Nyman, J A Vuorinen, K A Pyykkö, R A Lammintausta. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. Journal of clinical pharmacology. 1997 Jul; 37(7):602-9. doi: 10.1002/j.1552-4604.1997.tb04342.x. [PMID: 9243353]
  • H J Mascher, C Kikuta, A Millendorfer, H Schiel, G Ludwig. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. International journal of clinical pharmacology and therapeutics. 1997 Jan; 35(1):9-13. doi: NULL. [PMID: 9021435]
  • J Waitzinger, G Ludwig, G Pabst, K Michaelis, C Reh. Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). International journal of clinical pharmacology and therapeutics. 1996 Oct; 34(10):427-32. doi: NULL. [PMID: 8897080]
  • P Dostert, M Strolin Benedetti, S Persiani, R La Croix, M Bosc, F Fiorentini, D Deffond, D Vernay, G Dordain. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. Journal of neural transmission. Supplementum. 1995; 45(?):247-57. doi: . [PMID: 8748632]
  • G Szebeni, J Lengyel, G Székács, K Magyar, J Gaál, I Szatmári. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma. Acta physiologica Hungarica. 1995; 83(2):135-41. doi: NULL. [PMID: 8588500]
  • I Mahmood, S H Neau, W D Mason. An enzymatic assay for the MAO-B inhibitor selegiline in plasma. Journal of pharmaceutical and biomedical analysis. 1994 Jul; 12(7):895-9. doi: 10.1016/0731-7085(93)e0021-e. [PMID: 7981318]